Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead and Achillion initiate early trial of hepatitis C drug
During the trial, the companies will evaluate the pharmacokinetics, tolerability and safety of single escalating doses of GS 9132 in healthy volunteers. The study will take place in
During the trial, the companies will evaluate the pharmacokinetics, tolerability and safety of single escalating doses of GS 9132 in healthy volunteers. The study will take place in
The companies say that this is the first prescription osteoporosis therapy to include calcium. The new treatment option comes in light of a recent Surgeon General’s Report on
The FDA has informed the company in a preliminary communication that it still requires further information before it will grant its approval for the drug. The company has
According to the company one of these compounds has already shown repeated efficacy in blocking tumors in a pre-clinical model of breast cancer. Other compounds in the family
The company is currently in discussions with the Food and Drug Administration in order to finalize the details of this trial. The FDA has made recommendations regarding secondary
Prior to this approval the drug was only approved for use in people two years of age and older. The younger age indication for Vaqta was supported by
The market for preserving cells and tissue is growing rapidly and is diverging into new technology areas, one of which is vitrification, or freezing rapidly to avoid the
The grant was awarded under the foundation’s drug discovery and development program aimed at addressing obstacles that currently impede progress in bringing new Parkinson’s disease therapies to market.
This approval triggers the final milestone payment of $4 million to Upsher-Smith Laboratories under Unigene’s exclusive US licensing agreement. Fortical will be manufactured at Unigene’s production facility in
As part of the agreement, Labopharm could receive payments of up to $170 million, including an up-front licensing fee of $20 million, a payment of up to $40